An experimental therapy designed to mimic vitamin B12 and deliver a toxic molecule to tumor cells showed promise as a potential treatment for an aggressive…
News
GYNECOLOGICAL CANCER
Vaccine plus Keytruda bests standard care for hard-to-treat ovarian cancer
The experimental cancer vaccine Tedopi (OSE2101), when given in combination with the approved injection therapy Keytruda (pembrolizumab), outperforms standard-of-care treatment in delaying disease…
For World Blood Cancer Day this May 28 — a day when advocates around the globe join forces to raise awareness…
PANCREATIC CANCER
Oral namodenoson for pancreatic cancer to advance in clinical testing
Following “encouraging findings” from an early study, Can-Fite Biopharma is planning a clinical trial to test…
A Phase 1 clinical trial testing TLX101-Tx, Telix Pharmaceuticals‘ experimental treatment for glioblastoma (an aggressive form of glioma), has completed enrollment. The study,…
GYNECOLOGICAL CANCER
New therapy bests chemo at improving survival in endometrial cancer
A large clinical trial testing Merck’s therapy candidate sacituzumab tirumotecan (sac-TMT) in people with hard-to-treat endometrial cancer has achieved its main goal, with sac-TMT…
A Phase 1 clinical trial testing the experimental therapy KLN-1010 in people with relapsed or refractory multiple myeloma has begun treating patients in the…
The U.S. Food and Drug Administration (FDA) has approved a new combination therapy — Inqovi (decitabine and cedazuridine) plus Venclexta (venetoclax) — to treat adults…
The U.S. Food and Drug Administration (FDA) has given Actuate Therapeutics the green light to begin a clinical trial testing an oral formulation of…
In an early clinical trial testing the novel therapy Alpha DaRT for recurrent glioblastoma, the first three patients given the radiation treatment all showed a…
Recent Posts
- Experimental chemo combo may improve control of hard-to-treat AML
- Accepting moments of happiness amid the weight of caregiving
- 2 trials testing oral therapy for hard-to-treat myeloma are now recruiting
- New pancreatic cancer therapy moves into Phase 2/3 clinical testing
- FDA approves oral therapy Zenbexus for adults with hard-to-treat myeloma
